Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors. JAMA Oncol. 2016;2(12):1565–73.

Article  PubMed  Google Scholar 

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

Article  Google Scholar 

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427-38.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Truqap (capivasertib). Highlights of prescribing information. AstraZeneca; 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf.

US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2024. Available from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools.

Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, et al. Endocrine and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer—capivasertib-fulvestrant: ASCO Rapid Recommendation Update. J Clin Oncol. 2024;42(12):1450–3.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 6.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed 12 Nov 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95.

Article  CAS  PubMed  Google Scholar 

Nourieh M, Vibert R, Saint-Ghislain M, Cyrta J, Vincent-Salomon A. Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction. Histopathology. 2023;82(1):162–9.

Article  PubMed  Google Scholar 

Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21(1):79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raez LE, Brice K, Dumais K, Lopez-Cohen A, Wietecha D, Izquierdo PA, et al. Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clin Lung Cancer. 2023;24(2):120–9.

Article  CAS  PubMed  Google Scholar 

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.

Article  CAS  PubMed  Google Scholar 

Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van’t Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22(1):15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat. 2011;129(3):761–5.

Article  CAS  PubMed  Google Scholar 

Cheng S, Nguyen ET, Fukui JA. Utilizing liquid biopsy for treatment management in bone-dominant metastatic breast cancer: a case report. Case Rep Oncol. 2022;15(3):854–60.

Article  PubMed  PubMed Central  Google Scholar 

Bredno J, Venn O, Chen X, Freese P, Ofman JJ. Circulating tumor DNA allele fraction: a candidate biological signal for multicancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022;192(10):1368–78.

Article  CAS  PubMed  Google Scholar 

Armakolas A, Kotsari M, Koskinas J. Liquid biopsies, novel approaches and future directions. Cancers (Basel). 2023;15(5):1579.

Article  CAS  PubMed  Google Scholar 

Herberts C, Wyatt AW. Technical and biological constraints on ctDNA-based genotyping. Trends Cancer. 2021;7(11):995–1009.

Article  CAS  PubMed  Google Scholar 

Verzè M, Boscolo Bragadin A, Minari R, Pasello G, Perrone F, Scattolin D, et al. NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers. J Liquid Biopsy. 2024;4:100143.

Article  Google Scholar 

Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat. 2024;207(3):599–609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasi PM, Lee JK, Pasquina LW, Decker B, Vanden Borre P, Pavlick DC, et al. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types. Clin Cancer Res. 2024;30(4):836–48.

Article  CAS  PubMed  Google Scholar 

Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17(3):e0264138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15(9):e0237802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, et al. Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples. JCO Precis Oncol. 2022;6:e2200261.

Article  PubMed  PubMed Central  Google Scholar 

Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6(1):91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714–28.

Article  PubMed  Google Scholar 

Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, et al. Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. 2023;29(6):1056–67.

Article  CAS  PubMed  Google Scholar 

Leenanitikul J, Chanchaem P, Mankhong S, Denariyakoon S, Fongchaiya V, Arayataweegool A, et al. Concordance between whole exome sequencing of circulating tumor DNA and tumor tissue. PLoS ONE. 2023;18(10):e0292879.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, et al. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nat Commun. 2022;13(1):7495.

Article  CAS  PubMed  PubMed Central